Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman

This article was originally published in The Gray Sheet

Executive Summary

FDA is encouraging PMA sponsors to file a continued-access protocol for a long-term trial that will meet postmarket study requirements following a device's approval

You may also be interested in...



FDA Pushes Faster Post-Approval Study Starts In Drug-Eluting Stent Guidance

FDA's March 26 1draft guidance on nonclinical and clinical studies of drug-eluting coronary stents is the first device guidance to recommend that sponsors begin post-market studies before their device is approved

FDA Pushes Faster Post-Approval Study Starts In Drug-Eluting Stent Guidance

FDA's March 26 1draft guidance on nonclinical and clinical studies of drug-eluting coronary stents is the first device guidance to recommend that sponsors begin post-market studies before their device is approved

Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies

The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting

Related Content

UsernamePublicRestriction

Register

MT020559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel